Cargando…
A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332096/ https://www.ncbi.nlm.nih.gov/pubmed/35902867 http://dx.doi.org/10.1186/s13054-022-04096-9 |
| _version_ | 1784758564801216512 |
|---|---|
| author | Wagener, Gebhard Goldklang, Monica P. Gerber, Adam Elisman, Katerina Eiseman, Katherine A. Fonseca, Laura D. D’Armiento, Jeanine M. |
| author_facet | Wagener, Gebhard Goldklang, Monica P. Gerber, Adam Elisman, Katerina Eiseman, Katherine A. Fonseca, Laura D. D’Armiento, Jeanine M. |
| author_sort | Wagener, Gebhard |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9332096 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93320962022-07-28 A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 Wagener, Gebhard Goldklang, Monica P. Gerber, Adam Elisman, Katerina Eiseman, Katherine A. Fonseca, Laura D. D’Armiento, Jeanine M. Crit Care Correspondence BioMed Central 2022-07-28 /pmc/articles/PMC9332096/ /pubmed/35902867 http://dx.doi.org/10.1186/s13054-022-04096-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correspondence Wagener, Gebhard Goldklang, Monica P. Gerber, Adam Elisman, Katerina Eiseman, Katherine A. Fonseca, Laura D. D’Armiento, Jeanine M. A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 |
| title | A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 |
| title_full | A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 |
| title_fullStr | A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 |
| title_full_unstemmed | A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 |
| title_short | A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19 |
| title_sort | randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (txa-127) for the treatment of severe covid-19 |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332096/ https://www.ncbi.nlm.nih.gov/pubmed/35902867 http://dx.doi.org/10.1186/s13054-022-04096-9 |
| work_keys_str_mv | AT wagenergebhard arandomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT goldklangmonicap arandomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT gerberadam arandomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT elismankaterina arandomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT eisemankatherinea arandomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT fonsecalaurad arandomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT darmientojeaninem arandomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT wagenergebhard randomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT goldklangmonicap randomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT gerberadam randomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT elismankaterina randomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT eisemankatherinea randomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT fonsecalaurad randomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 AT darmientojeaninem randomizedplacebocontrolleddoubleblindedpilotstudyofangiotensin17txa127forthetreatmentofseverecovid19 |